Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 681-695

  Elokdah, Hassan ^a   Sulkowski, Theodore S ^a   Abou Gharbia, Magid ^a   Butera, John A ^a   Chai, Sie Yearl ^a   McFarlane, Geraldine R ^a   McKean, Mar Lee ^a   Babiak, John L ^a,b   Adelman, Steven J ^a   Quinet, Elaine M ^a  

^a PFIZER INC   (United States)

^b PTC THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANOIMIDAZOLIDIN 4 ONE DERIVATIVE; 2 THIOHYDANTOIN DERIVATIVE; 2 THIOPARABANIC ACID; 2 THIOPIPERAZINE 4 ONE DERIVATIVE; 3 THIOXO 1,2,4 OXADIAZINAN 5 ONE; APOLIPOPROTEIN A1; CHOLESTEROL; DIAZEPANONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDANTOIN DERIVATIVE; IMIDAZOLE DERIVATIVE; LIVER ENZYME; SULFANYLDIHYDROIMIDAZOLONE; THIOL DERIVATIVE; THIOURACIL; THYROXINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYCLIZATION; DOSE RESPONSE; DRUG SYNTHESIS; HAMSTER; LINEAR REGRESSION ANALYSIS; LIPID BLOOD LEVEL; LIVER; MALE; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CHOLESTEROL, HDL; CRICETINAE; DRUG DESIGN; GUANIDINES; HYPERCHOLESTEROLEMIA; IMIDAZOLES; MALE; PIPERAZINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; STIMULATION, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES; THIOHYDANTOINS; THIONES;

EID: 9144244786     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030219z     Document Type: Article

References (44)

1. Rosamond, W. D.; Chambless, L. E.; Folsom, A. R.; Cooper, L. S.; Conwill, D. E.; Clegg, L.; Wang, C.-H.; Heiss, G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N. Engl. J. Med. 1998, 339, 861-867.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994, 344, 1383-1389.
3. Shepherd, J.; Cobbe, S. M.; Ford, I.; Isles, C. G.; Lorimer, A. R.; Macfarlane, P. W.; McKillop, J. H.; Packard, C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland coronary prevention study group. N. Engl. J. Med. 1995, 333, 1301-1307.
4. Sacks, F. M.; Pfeffer, M. A.; Moye, L. A.; Rouleau, J. L.; Rutherford, J. D.; Cole, T. G.; Brown, L.; Warnica, J. W.; Arnold, J. M. O.; Wun, C.-C.; Davis, B. R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and recurrent events trial investigators. N. Engl. J. Med. 1996, 335, 1001-1009.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N. Engl. J. Med. 1998, 339, 1349-1357.
6. Downs, J. R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D. R.; Beere, P. A.; Langendorfer, A.; Stein, E. A.; Kruyer, W.; Gotto, A. M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS (Air Force/Texas coronary atherosclerosis prevention study). J. Am. Med. Assoc. 1998, 279, 1615-1622.
7. Superko, H. R. Beyond LDL cholesterol reduction. Circulation 1996, 94, 2351-2354.
8. Miller, G. J.; Miller, N. E.; Plasma high-density-lipoprotein concentration and development of ischaemic heart disease. Lancet 1975, 1, 16-19.
9. Gordon, D. J.; Probstfield, J. L.; Garrison, R. J.; Neaton, J. D.; Castelli, W. P.; Knoke, J. D.; Jacobs, D. R.; Bangdiwala, S.; Tyroler, H. A. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989, 79, 8-15.
10. Franceschini, G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am. J. Cardiol. 2001, Dec 20, 88(12A), 9N-13N.
11. Assmann, G.; Schulte, H.; von Eckardstein, A.; Huang, Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124, Suppl S11-20.
12. Glomset, J. A. The plasma lecithin: cholesterol acyl-transferase reaction. J. Lipid Res. 1968, 9, 155-167.
13. Tall, A. R. Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 1990, 86(2), 379-384.
14. Barter, P. J.; Rye, K. Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. 1996, 7, 82-87.
15. Elokdah, H.; Sulkowski, T.; Cochran, D.; McKean, M.-L.; Quinet, E. Effects of 2-(substituted-sulfanyl)-3,5-dihydro-imidazole-4-one and 2-(substituted-sulfanyl)-1H-imidazole-4,5-dione derivatives on serum HDL-cholesterol. Bioorg. Med. Chem. Lett. 2000, 10(16), 1791-1794.
16. Schutkowski, M.; Mrestani-Klaus, C.; Neubert, K. Synthesis of dipeptide 4-nitroanilides containing nonproteinogenic amino acids. Int. J. Pept. Protein Res. 1995, 45(3), 257-265.
17. Ulrich, H.; Sayigh, A. A. R. The Reaction of Oxalyl Chloride with Substituted Ureas and Thioureas. J. Org. Chem. 1965, 30, 2781-2783.
18. Kornowski, H.; Trichot, M.; Delage, B. 1,2,4-Oxadiazines. II. Preparation of N2- or N4-mono- or dimethyl derivatives. Bull. Soc. Chim. Fr. 1966, (2), 683-686.
19. Cava, M. P.; Levinson, M. I. Thionation Reactions of Lawesson's Reagents. Tetrahedron 1985, 41(22), 5061-5087.
20. France, D. S.; Quinby, R. E.; Babiak, J. L.; Paterniti, D. C.; Weinstein, J. R.; D. B. Lab. Rob. Autom. 1990, 2, 155.
21. Imaizumi, K.; Nagatomi, A.; Sato, M.; Tominaga, A.; Sugano, M. Cholesterol metabolism in ExHC (exogenous hypercholesterolemic) rats. Biochim. Biophys. Acta 1992, 1123(1), 101-109.
22. Krause, B. R.; Princen, H. M. Lack of predictability of classical animal models for hypolipidemic activity: A good time for mice? Atherosclerosis 1998, 140(1), 15-24.
23. Durant, G. J.; Emmett, J. C.; Ganellin, C. R.; Miles, P. D.; Parsons, M. E.; Prain, H. D.; White, G. R. Cyanoguanidine-Thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine. J. Med. Chem. 1977, 20(7), 901-906.
24. Manley, P. W.; Quast, U. Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethene-diamines, thioureas, and ureas. J. Med. Chem. 1992, 35(12), 2327-2340.
25. Gilman, A. G.; Murad, F. In Pharmaceutical basis of therapeutics; Goodman, L. S., Gilman, A., Eds.; Macmillan: New York, 1975; pp 1410-1415.
26. Spady, D. K.; Dietschy, J. M. Interaction of Dietary Cholesterol and Triglycerides in the Regulation of Hepatic Low-Density Lipoprotein Transport in the Hamster. J. Clin. Invest. 1988, 81, 300-309.
27. Kawashiri, M. A.; Maugeais, C.; Rader, D. J. High-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis, review. Curr. Atheroscler. Rep. 2000, 2(5), 363-372.
28. Rader, D. J.; Maugeais, C. Genes influencing HDL metabolism: New perspectives and implications for atherosclerosis prevention, Review, Mol. Med. Today 2000, 6(4), 170-175.
29. Krause, B. R.; Auerbach, B. J. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 2001, 2(3), 375-381.
30. McKean, M. L.; Quercia, S. M.; Ponticiello, R.; Clark, D. E.; Quinet, E. M.; Adelman, S. J. WAY-135433 increases plasma HDL cholesterol and post-heparin lipoprotein lipase activity in cynomolgus monkeys. Suppl. Circulation 1998, 98, 1-663.
31. Elokdah, H.; Sulkowski, T.; Chai, S.-Y.; McFarlane, G.; Butera, J.; McKean, Mar-Lee; Quinet, E. Design and synthesis of thioxoimidazolidine-diones and derivatives as high-density lipoprotein cholesterol (HDL-C) enhancers. Abstracts of Papers, 222nd National Meeting of the American Chemical Society, 2001; American Chemical Society: Washington, DC; ORGN-419.
32. Duverger, N.; Knith, H.; Emmanuel, F.; Caillaud, J. M.; Viglietta, C.; Castro, G.; Tailleux, A.; Fievet, C.; Fruchart, J. C.; Houdebine, L. M.; Denefle, P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996, 9, 713-717.
33. Rubin, E. M.; Krauss, R. M.; Spangler, E. A.; Veratuyft, J. G.; Clitt, S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991, 353, 265-267.
34. Plump, A. S.; Scott, C. J.; Breslow, J. L. Human apolipoprotein A-I gene expression increases high-density lipoprotein and suppresses atherosclerosis in the apolipoprotein H-deficient mouse. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9607-9611.
35. Jonas, A.; von Eckardstein, A.; Kezdy, K. E.; Steinmetz, A.; Assmann, G. Structural and functional properties of reconstituted high-density lipoprotein discs prepared with six apolipoprotein A-I variants. J. Lipid Res. 1991, 32, 97-106.
36. Lawn, R. M.; Wade, D. P.; Garvin, M. R.; Wang, X.; Schwartz, K.; Porter, J. G.; Seilhamer, J. J.; Vaughan, A. M.; Oram, J. F. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 1999, 104, R25-31.
37. Goldberg, I. J.; Blaner, W. S.; Vanni, T. M.; Moukides, M.; Ramakrishnan, R. J. Clin. Invest. 1990, 86, 463-473.
38. Reymer, P. W.; Gagne, E.; Groenemeyer, B. E.; Zhang, H.; Forsyth, I.; Jansen, H.; Seidell, J. C.; Kromhout, D.; Lie, K. E.; Kastelein, J.; Hayden, M. R. A lipoprotein lipase mutation (Asn291Scr) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat. Genet. 1995, 10, 28-34.
39. Redgrave, T. D.; Small, D. M. Quantitation of the transfer of surface phospholipid of chylomicrons to the high-density lipoprotein fraction during the catabolism of chylomicrons in the rat. J. Clin. Invest. 1979, 64, 162-171.
40. Tall, A. R.; Blum, C. B.; Forester, G. P.; Nelson, C. A. Changes in the distribution and composition of plasma high-density lipoproteins after ingestion of fat. J. Biol. Chem. 1982, 257, 198-207.
41. Wilson, T. A.; Nicolosi, R. J.; Lawton, C. W.; Babiak, J. Gender differences in response to a hypercholesterolemic diet in hamsters: Effects on plasma lipoprotein cholesterol concentrations and early aortic athersclerosis. Atherosclerosis 1999, 146, 83-91.
42. Burkey, B. F.; France, D.; Wang, H.; Ma, X.; Brand, B.; Abuhani, C.; Diffenderfer, M. R.; Marsh, J. B.; Paterniti, J. R., Jr.; Fisher, E. A. Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis. J. Lipid. Res. 1995, 36(7), 1463-1473.
43. Loh, T.-P.; Wei, L.-L. Indium trichloride-catalyzed conjugate addition of amines to α,β-ethylenic compounds in water. Synlett. 1998, 9, 975-976.
44. Spengler, J.; Burger, K. An efficient synthesis of N-methyl amino acids and some of their derivatives. Synthesis 1998, 1, 67-70.